Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PneumoMICI: Anti-pneumococcal Vaccine Strategy in CIBD
NCT02255227Phase 2Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Apr 2015
- Primary completion
- Aug 2019
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pneumococcal 13-valent conjugate vaccine in pneumococcal infection, sponsored by CHU Saint-Etienne. Started Apr 2015; status: terminated.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02255227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255227.